Litcius/Paper detail

Mirvetuximab Soravtansine: First Approval

Young‐A Heo

2023Drugs106 citationsDOIOpen Access PDF

Topics & Concepts

MedicineFallopian tubeOvarian cancerImmunogenAntibody-drug conjugateAntibodyConjugateInternal medicineGynecologyAntibody therapyOncologyDrug holidayPharmacologyMonoclonal antibodyCancerImmunologyHuman immunodeficiency virus (HIV)MathematicsMathematical analysisOvarian cancer diagnosis and treatmentPARP inhibition in cancer therapyAdvanced Breast Cancer Therapies
Mirvetuximab Soravtansine: First Approval | Litcius